Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Christopher D. O'Brien"'
Autor:
Ngozi Erondu, Mark Curran, Colin Feuille, Olivia Roberson, Jonathan Y. Shih, Yao-Wen Cheng, Benjamin E. Rubin, Saquib Rahim, Christel Chehoud, Yongmei Shi, David Apfel, Nicholas Skomrock, Najat S. Khan, Uma Mahadevan, Atul J. Butte, Vivek A. Rudrapatna, Arman Mosenia, Natalie A. Terry, Benjamin D Martini, Christopher D. O'Brien
Publikováno v:
PloS one, vol 18, iss 3
ObjectivesThe use of external control arms to study treatment effects is growing in interest among drug sponsors and regulators. However, experience with performing these kinds of studies for complex, immune-mediated diseases is limited. We sought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07cbb0a3f68c0ec44a318ba6c579e45c
https://doi.org/10.1101/2021.11.12.21266064
https://doi.org/10.1101/2021.11.12.21266064
Autor:
Silvio Danese, Bruce E. Sands, Maria T. Abreu, Christopher D. O’Brien, Ivana Bravatà, Maciej Nazar, Ye Miao, Yanli Wang, David Rowbotham, Rupert W.L. Leong, Ramesh P. Arasaradnam, Waqqas Afif, Colleen Marano
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:2858-2867.e5
Rapid symptomatic relief is an important treatment goal for patients with ulcerative colitis (UC). We aimed to characterize early response with ustekinumab in patients with moderate-to-severe UC during the initial 16 weeks of treatment.We performed a
Autor:
Stanley A. Cohen, Dan Turner, Anne M. Griffiths, Omoniyi J. Adedokun, Douglas A Jacobstein, Christopher D. O'Brien, Jeffrey S. Hyams, Lakshmi Padgett, Joel R. Rosh, Natalie A. Terry
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims The objective was to evaluate the pharmacokinetics, safety/tolerability, and efficacy of ustekinumab in children with moderately to severely active Crohn’s disease. Methods In this Phase 1, multicentre, 16-week, double-blind, in
Publikováno v:
The FASEB Journal. 35
Publikováno v:
The FASEB Journal. 35
Autor:
Jacqueline Perrigoue, Luciana R. Muniz-Bongers, Luvena L. Ong, Yanqing Chen, Leon Chang, Karen Ngo, Aleksandar Stojmirovic, Christopher D. O’Brien, Matthew Germinaro, Rajesh Rao, Marion Vetter, Jennifer Towne
Publikováno v:
Gastroenterology. 162:S-794
Autor:
Michelle Ge, Bin Chen, Yichuan Karen Xia, Elliot S. Barnathan, Robin L. Thurmond, Matthew J. Loza, A. Kollmeier, Philip E. Silkoff, Bei Zhou, Christopher D. O'Brien
Publikováno v:
Annals of Allergy, Asthma & Immunology. 121:568-574
Background Data from preclinical and clinical studies support the evaluation of histamine 4 receptor antagonists in the treatment of asthma. Toreforant is a selective histamine 4 receptor antagonist that could be effective in patients with eosinophil
Autor:
Remo, Panaccione, Silvio, Danese, William J, Sandborn, Christopher D, O'Brien, Yiying, Zhou, Hongyan, Zhang, Omoniyi J, Adedokun, Ilia, Tikhonov, Stephan, Targan, Maria T, Abreu, Tadakazu, Hisamatsu, Ellen J, Scherl, Rupert W, Leong, David S, Rowbotham, Ramesh P, Arasaradnam, Bruce E, Sands, Colleen, Marano
Publikováno v:
Aliment Pharmacol Ther
BACKGROUND: The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab treatment for moderate-to-severe ulcerative colitis (UC) from Weeks 44 through 220. AIMS: To assess efficacy (through Week 92) and safety (through week 96) during th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8377c12357768830ffb2a85b1ddd9ebc
https://europepmc.org/articles/PMC8776399/
https://europepmc.org/articles/PMC8776399/
Autor:
Joel R. Rosh, Anne M. Griffiths, Jeffrey S. Hyams, Geneviève Veereman, Melvin B. Heyman, Omoniyi J. Adedokun, Daphne Chan, Christopher D. O'Brien, Richard Strauss, Ghassan Wahbeh, Dan Turner, John P. Lynch, Lakshmi Padgett
Publikováno v:
Crohn's & colitis 360, vol 2, iss 4
Background Long-term safety, pharmacokinetics, and efficacy of open-label golimumab therapy in children with moderate–severe ulcerative colitis were evaluated. Methods Week-6 golimumab responders (Mayo score decrease of ≥30% and ≥3 points from
Autor:
Subrata Ghosh, Bruce E. Sands, Elyssa Ott, Brian G. Feagan, Christopher Gasink, Silvio Danese, Colleen Marano, Yiying Zhou, Sheri Volger, Thomas Baker, William J. Sandborn, Christopher D. O'Brien, Ilia Tikhonov
Publikováno v:
Inflammatory Bowel Diseases
Background Ustekinumab is currently approved globally in Crohn’s disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn’s disease and UC phase 3 programs had similar study designs, f